The price of MGNX is predicted to go up -0.4%, based on the high correlation periods with PAA. The similarity of these two price pattern on the periods is 95.81%.
MGNX
PAA
Down: -0.4%Similarity: 95.81%
MGNX Revenue Forecast
MGNX EPS Forecast
MGNX FAQs
What is bull’s view on MGNX?
MGNX stock has a bullish view due to its recent earnings surprise, reporting $0.90 EPS against an expected $0.17, and revenue of $110.71M, exceeding estimates by 14.09%. Despite a 61.5% YTD decline, the stock's valuation improved from 48% to 60% based on fundamentals, suggesting moderate recovery potential. Analysts' price target of $4 implies limited upside, but strong financial leadership changes and pipeline progress could drive future growth.
What is bear's view on MGNX?
MGNX stock currently trades at $4.19, with a bearish outlook due to its 61.5% YTD decline despite a recent earnings beat. The upcoming leadership transition and projected Q4 loss of $0.21 per share raise concerns about management stability and profitability. Analysts' ratings are mixed, with a recent downgrade to "Hold," reflecting limited upside potential.
What is MGNX revenue forecast for next quarter?
The market consensus for MGNX's revenue in the upcoming quarter is projected to be approximately $9.325M USD.
JMP Securities analyst Silvan Tuerkcan downgraded MacroGenics to Market Perform from Outperform without a price target. The company "is in a holding pattern" with respect to its pipeline, has paused all vobra duo development, including the lorigerlimab combo, and sold Margenza, the analyst tells investors in a research note. The firm cites the uncertain future of MacroGenics' B7-H3 franchise and lack of data and clarity on lorigerlimab and the DART programs for the downgrade. It views the shares as fairly valued currently.